Cortexyme Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark Office
August 27 2020 - 8:00AM
Business Wire
- New U.S. Patent No. 10,730,826 provides
additional composition of matter protection for atuzaginstat
(COR388)
- The '826 patent extends the patent term for
atuzaginstat to 2037, with a possible patent term extension of up
to an additional five years
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage
biopharmaceutical company pioneering potential therapeutics for
Alzheimer’s and other degenerative diseases, announced today that
the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent
No. 10,730,826 relating to Cortexyme’s lead small molecule,
atuzaginstat (COR388).
Cortexyme's ‘826 patent provides additional composition of
matter protection for atuzaginstat and gingipain inhibitors, with
additional claims pending in related applications. The patent is
expected to provide patent protection for atuzaginstat through
September 2037, not including a possible patent term extension of
up to five years as provided under the Drug Price Competition and
Patent Restoration Act (35 U.S.C. §156).
Casey Lynch, Cortexyme’s chief executive officer, co-founder,
and chair commented: "We are particularly excited about the
issuance of this composition of matter patent for atuzaginstat in
anticipation of upcoming results from our GAIN Phase 2/3 clinical
trial in the fourth quarter of 2021. The USPTO's issuance of this
patent strengthens our intellectual property protection for
gingipain inhibitors and atuzaginstat. This patent further supports
our ongoing R&D efforts to develop treatments for Alzheimer's
and other degenerative diseases and supports the potential
expansion of our pipeline into additional indications."
About Cortexyme, Inc.
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage
biopharmaceutical company pioneering upstream therapeutic
approaches designed to improve the lives of patients diagnosed with
Alzheimer’s and other degenerative diseases. Based upon the
evidence generated to date, Cortexyme is currently advancing its
lead therapeutic candidate, atuzaginstat (COR388), in the GAIN
Trial, an ongoing Phase 2/3 clinical trial in patients with mild to
moderate Alzheimer’s disease. Cortexyme is targeting a specific,
infectious pathogen found in the brain of Alzheimer’s patients and
tied to neurodegeneration and neuroinflammation in animal models.
To learn more about Cortexyme, visit www.cortexyme.com or follow
@Cortexyme on Twitter.
Forward-Looking
Statements
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“expect,” “believe,” “will,” “may,” “should,” “estimate,”
“project,” “outlook,” “forecast” or other similar words. Examples
of forward-looking statements include, among others, statements we
make regarding our business plans and prospects, cash forecasts,
the timing and success of our clinical trials and related data,
ability to fund planned operating and capital expenditures, the
timing of announcements and updates relating to our clinical trials
and related data, the timing of and our ability to enroll patients
into our clinical trials, and the potential therapeutic benefits,
safety and efficacy of our product candidates or library of
compounds in the potential treatment of Alzheimer’s Disease and
additional indications. Forward-looking statements are based on
Cortexyme’s current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict
and could cause actual results to differ materially from what we
expect. Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Factors that could cause actual results to differ include, but are
not limited to, the risks and uncertainties described in the
section titled “Risk Factors” in our Annual Report on Form 10-K
filed with the Securities and Exchange Commission (SEC) on March
16, 2020, our Quarterly Report on Form 10-Q filed with the SEC on
August 14, 2020, and other reports as filed with the SEC.
Forward-looking statements contained in this press release are made
as of this date, and Cortexyme undertakes no duty to update such
information except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200827005397/en/
Investor Contact: Chris Lowe Cortexyme, Inc. Chief
Financial Officer clowe@cortexyme.com
Media Contact: Hal Mackins For Cortexyme, Inc.
hal@torchcomllc.com (415) 994-0040
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Apr 2023 to Apr 2024